Compass stock heads north on psychedelic’s Phase III TRD success
Compass will now seek approval for COMP360, which could become the first classic psychedelic to gain the FDA’s blessing.
18 February 2026
18 February 2026
Compass will now seek approval for COMP360, which could become the first classic psychedelic to gain the FDA’s blessing.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.